Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $219.5MThe company’s own SEC segment disclosure.
- ORLADEYO$158.2M72%
- License Revenue And Other Income From Contract With Customer$60.0M27%
- Research And Development Services$1.2M1%
BioCryst Pharmaceuticals, Inc. (BCRX) reported revenue of $218M in Q2 2026 (quarter ended Jun 30, 2026), up 34% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $78M (36% of revenue). For the full year FY2025, revenue was $875M (+94% year on year) and net income $264M. Its largest product in Q2 2026 was ORLADEYO at $158M, 72% of the disclosed total, well ahead of License Revenue And Other Income From Contract With Customer at 27%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #28 of 29 by Smart Score